Xeltis
San Francisco, California, United States · Biotechnology, Health Care, Manufacturing
Xeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels. The Company seeks to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. Xeltis' proprietary endogenous tissue restoration (ETR) platform utilizes an advanced
Key facts
- Headquarters
- San Francisco, California, United States
- Employees
- 85
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Private
- Website
- xeltis.com
- Company page
Recent activity at Xeltis
- : Xeltis raises an additional €20.5m to advance aXess™ toward FDA approval and US commercial launch with Horizon 3 Healthcare as the lead investor.
- : Xeltis secures nearly €50m to advance aXess, its vascular access conduit, from the EIB and existing shareholders.
- : Xeltis Appoints Luc Verhees as Vice President of Clinical Business Development
- : Xeltis Appoints Shawn Gage as Vice President of US Clinical Affairs
Xeltis funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Venture | $20.5M |
| Dec 2025 | Funding Round | $50.0M |
Leadership
- Rob Eyers, CTO @ Xeltis | Medical Device Consultant
- Alexander Goemans, CFO
- Eliane Schutte, Chief Executive Officer
- Luc Verhees, Vice President
- Shawn Gage, Vice President
Verified email and direct lines for Xeltis’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Xeltis in the news
- Xeltis has first commercial implant of vascular access device for hemodialysis - MassDevice (Jul 07, 2026)
- Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch - GlobeNewswire (Jul 28, 2026)
- Xeltis Receives IDE Approval from FDA for Initiation of US Pivotal Trial for aXess, its Restorative Vascular Access Conduit - Diagnostic and Interventional Cardiology (Jun 13, 2024)
- Sarasota Memorial Participates in Research Study Testing aXess™ Dialysis Conduit - Florida Hospital News and Healthcare Report (Oct 16, 2025)
- Percutaneous pulmonary valve implantation in a failed novel biorestorative valved conduit - Termedia (Jun 30, 2023)
Companies similar to Xeltis
- InspireMD · Biotechnology, Health Care, Manufacturing
- Atomo Diagnostics · Biotechnology, Health Care, Manufacturing
- PROTEOR · Biotechnology, Health Care, Manufacturing
- KMM Group · Biotechnology, Health Care, Manufacturing
- Velentium Medical · Biotechnology, Health Care, Manufacturing
About Xeltis: questions and answers
What does Xeltis do?
Xeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels. The Company seeks to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. Xeltis' proprietary endogenous tissue restoration (ETR) platform utilizes an advanced
Where is Xeltis headquartered?
Xeltis is headquartered in San Francisco, California, United States.
How many employees does Xeltis have?
Xeltis has about 85 employees.
Has Xeltis raised funding?
Yes. Fundz has recorded 2 funding events for Xeltis. The most recent, $20.5M, was in Jul 2026.
Who leads Xeltis?
Eliane Schutte is a Chief Executive Officer at Xeltis.
What is the latest news on Xeltis?
On Jul 28, 2026, Xeltis raises an additional €20.5m to advance aXess™ toward FDA approval and US commercial launch with Horizon 3 Healthcare as the lead investor.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy